How Can We Sustain the Innovation of Biopharmaceuticals?

Welcome to the Specialty Pharmacy Collaboration Summit Podcast Series. Today we are speaking with Robert Popovian, Senior Director, US Government Relations, Pfizer Pharmaceuticals.

Download the complete podcast & transcript here.

What needs to happen in the US to sustain the innovation initiative of biopharmaceuticals?

Robert: Well, biopharmaceuticals is a complex issue and a lot of people try to make it a very simple one by saying to do regulatory reform through the FDA or provide additional NIH funding to do research. Biopharmaceutical innovation policies are very complex and inter-dependent onto one another. There is no one magic bullet.

So, there are three distinct environments that need to be addressed to really sustain the biopharmaceutical innovation marketplace in the US and that is the investment environment, which is basically appropriate and electoral property protection. For example, tax policy, ability to price medicines according to the marketplace.

There is the regulatory environment, which is the second environment, which requires that we do a better job of streamlining not only the FDA, but other regulatory bodies like the Centers for Disease Control. And then, more importantly, within the regulatory policy framework is how to better do clinical trials and clinical trial recruitment. That needs to be addressed.

Finally, it is the access, which in my opinion is the one that is short shifted a lot of times because unless you address the access environment for biopharmaceutical, no matter if you are investing a lot of money in it or you have a very deregulatory process to get the product out, if the patients are unable to access those medicines because they are too high cost regarding out-of-pocket costs or there is no meaningful way to get access to it because there is no way to communicate that information to the providers, innovation will suffer and patients will suffer long term with that.

Click here to download the rest of the podcast.

To hear more from Robert, please join him at IIR's Specialty Pharmacy Collaboration Summit, September 15-17 in Boston. Also, you can save an EXTRA $100 off the current rate, $500 in total savings when registering by 7/25 with the code: XP1968BLOG - Register now. 

See you in Boston!

Q&A with Amy Ramazio of GlaxoSmithKline – A Speaker at IIR’s Gross-to-Net Accounting Forum

At IIR's 2nd Annual Gross-to-Net Accounting Pharmaceutical Manufacturers, Amy Ramazio, Finance Director at GlaxoSmithKline will be the Big Pharma Chairperson, in our all new tailored discussion groups for your specific company size and function!

Below Amy sat down to do a quick Q&A session with us...enjoy!


Q&A:

1. How feasible is collaboration between managed markets, commercial, government programs and Finance?

Successful collaboration will largely depend on the particular individuals involved.  The key is for everyone to have an enterprise view.

2. Key questions to ask before investing and building an automated GTN system?

- What functionality is most important to your organization?
- How much are you willing to invest?
- When do you need the system to go live?

3. How to accrue and forecast patient/ payer related items? What critical/essential information is required and what aspects you can’t afford to overlook.

Forecasting and accruals are typically based on past history with some adjustments where there are specific changes expected in the future.  Having information to develop these adjustments is critical and could include: segment lives and expected trends, TRX data, formulary changes, legislation changes.   


To hear more from Amy, please join us in Philadelphia, June 17-18 for the 2nd Annual Gross-to-Net Accounting Forum. Plus register with the code XP1911BLOG to receive $100 off the current rate!

Register Now!

Register for the Oncology Management Summit by Friday 5/23 to Save $400!

The recent debate over healthcare reforms has made one thing clear: unsustainable costs are leading to fundamental shifts in the way cancer care is delivered. There is a growing expectation that healthcare represents good "value".

As a stakeholder within the cancer care value chain many complex issues vie for your time and attention. You must simultaneously grasp the big picture, staying abreast of the changing oncology landscape, and keep focused on the day-to-day concerns that impact delivery of effective and efficient patient care. At IIR's Oncology Management Summit you will walk away with solutions to the most critical issues: cost, access to care, incorporating new technology, and meeting standards for patient-centered care. Oncology pioneers provide an understanding of the big picture, but also with practical, useful information to help you improve care now.

IIR's Annual Summit for Oncology Management is your 360° view of the cancer value chain; where stakeholders and influencers including payers, providers, hospital systems, leading cancer centers, and pharmaceutical executives convene to discuss how to control costs, increase quality, determine value and improve overall patient experience for cancer care.

For a more detailed look into the Oncology Management Summit, download the agenda.

To learn more about the evolution of cancer care, join us July 21-23 in Philadelphia, PA. Register by this Friday – May, 23rd and save $400! Just use the code: XP1914BLOG


Register Today!